NCT01238952View on ClinicalTrials.gov

Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

March 31, 2013

Conditions
Advanced Solid TumorsMetastatic Triple Negative Breast Cancer
Interventions
DRUG

NK012 and carboplatin

NK012 and carboplatin via infusion once every 28 days

Trial Locations (1)

Unknown

Sarah Cannon Research Institute, Nashville

Sponsors
All Listed Sponsors
lead

Nippon Kayaku Co., Ltd.

INDUSTRY